MAP2K7 and neoplasm: Comparison of the sensitivity of patient derived tumor cells with the sensitivity of primary cultures previously derived from three urothelial bladder carcinomas and one small-cell neuroendocrine bladder carcinoma with no known MAPK pathway activating mutations [1] confirmed the selective sensitivity of the urachal cancer cells to the mTORC1/2 inhibitor AZD2014, MEK inhibitor trametinib and EFGR inhibitor afatinib (Supplementary Figure 2).